Established in 2003, BIOAXXESS started as a UK technology and business consultancy for innovative research biochemicals and diagnostics kits.

Since 2011 BIOAXXESS acts as the distributor of VLVbio (formerly PEVIVA AB) for customers in the UK and the Republic of Ireland (ROI).

Our scientific and technical expertise with PEVIVA's M30 and M65 ELISA and Cytokeratin-18 antibodies stems back to 2003. This was when BIOAXXESS started trading as a business and technology development agency for PEVIVA (now VLVbio) in Europe.

The list of Cytokeratin-18 projects initiated and coached to a successful conclusion, includes efficacy and safety testing for drug development in oncology, but also diagnostic applications in hepatology (NASH, NAFLD and AoCLD), sepsis and Graft-versus-Host Disease (GvHD).

Through our long-standing and broad experience of our in-house PhD-level expertise, we are able to support your project, whether you are based at a university, hospital, CRO, clinical research centre or working on R&D within pharma and biotech.

We serve customers from >50 UK hospitals and universities, but also pharma and biotech in R&D and through CROs for drug safety and mechanistic cell death biomarker analysis in clinical trials. Through our long-standing unique assay insight and close collaboration with key opinion leaders, BIOAXXESS becomes your partner of choice for your biomarker project.